Attached files

file filename
EX-21.1 - LIST OF SUBSIDIARIES - Jazz Pharmaceuticals plcjazzq42015ex211.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULES 13A-14(A) AND 15D-14(A) - Jazz Pharmaceuticals plcjazzq42015ex312.htm
EX-10.5 - MANUFACTURING SERVICES AGREEMENT - Jazz Pharmaceuticals plcjazzq42015ex105.htm
EX-32.1 - CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 - Jazz Pharmaceuticals plcjazzq42015ex321.htm
EX-10.23 - EXECUTIVE CHANGE IN CONTROL PLAN - Jazz Pharmaceuticals plcjazzq42015ex1023.htm
EX-10.22B - CASH BONUS PLAN U.S. - Jazz Pharmaceuticals plcjazzq42015ex1022b.htm
EX-10.22D - CASH BONUS PLAN OTHER - Jazz Pharmaceuticals plcjazzq42015ex1022d.htm
10-K - ANNUAL REPORT ON FORM 10-K - Jazz Pharmaceuticals plcjazz1231201510k.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULES 13A-14(A) AND 15D-14(A) - Jazz Pharmaceuticals plcjazzq42015ex311.htm
Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors
Jazz Pharmaceuticals plc:
We consent to the incorporation by reference in the registration statements (No. 333-202269, No. 333-194131, No. 333-186886 and No. 333-179075) on Form S-8 of Jazz Pharmaceuticals plc of our reports dated February 23, 2016, with respect to the consolidated balance sheets of Jazz Pharmaceuticals plc as of December 31, 2015 and 2014, and the related consolidated statements of income, comprehensive income (loss), shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2015, and the related financial statement schedule, and the effectiveness of internal control over financial reporting as of December 31, 2015, which reports appear in the December 31, 2015 annual report on Form 10-K of Jazz Pharmaceuticals plc.


 

/s/ KPMG
 
Dublin, Ireland
February 23, 2016